DE60032459D1 - Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1 - Google Patents

Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1

Info

Publication number
DE60032459D1
DE60032459D1 DE60032459T DE60032459T DE60032459D1 DE 60032459 D1 DE60032459 D1 DE 60032459D1 DE 60032459 T DE60032459 T DE 60032459T DE 60032459 T DE60032459 T DE 60032459T DE 60032459 D1 DE60032459 D1 DE 60032459D1
Authority
DE
Germany
Prior art keywords
restenosis
atherosclerosis
angiopoietin
vegf receptor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032459T
Other languages
English (en)
Inventor
E Epstein
Ran Kornowski
Shmuel Fuchs
Martin Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedStar Research Institute
Original Assignee
MedStar Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedStar Research Institute filed Critical MedStar Research Institute
Application granted granted Critical
Publication of DE60032459D1 publication Critical patent/DE60032459D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
DE60032459T 1999-01-15 2000-01-05 Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1 Expired - Fee Related DE60032459D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11597799P 1999-01-15 1999-01-15
PCT/US2000/000161 WO2000041712A1 (en) 1999-01-15 2000-01-05 Inhibiting development of microvessels within vascular walls

Publications (1)

Publication Number Publication Date
DE60032459D1 true DE60032459D1 (de) 2007-02-01

Family

ID=22364512

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032459T Expired - Fee Related DE60032459D1 (de) 1999-01-15 2000-01-05 Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1

Country Status (9)

Country Link
US (2) US20030191055A1 (de)
EP (1) EP1146891B1 (de)
JP (1) JP2002534475A (de)
AT (1) ATE348629T1 (de)
AU (2) AU773050B2 (de)
CA (1) CA2359461A1 (de)
DE (1) DE60032459D1 (de)
HK (1) HK1041447A1 (de)
WO (1) WO2000041712A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057722A1 (en) * 1999-03-30 2006-03-16 Myocardial Therapeutics, Inc. Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
CA2450954A1 (en) * 2001-06-20 2003-01-03 Imclone Systems Incorporated Method of treating atherosclerosis and other inflammatory diseases
DK1487856T3 (da) * 2002-03-04 2010-10-18 Imclone Llc KDR-specifikke humane antistoffer og deres anvendelse
WO2004087736A2 (en) * 2003-03-27 2004-10-14 The Texase A & M University System Uses of vascular endothelial growth factor and type i collagen inducible protein (vcip)
WO2004113384A1 (de) * 2003-06-18 2004-12-29 Georg-August-Universität Göttingen Verwendung eines vegf-rezeptorgens oder -genprodukts
US20090221673A1 (en) * 2005-09-13 2009-09-03 Rigby William F C Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
WO2008152507A2 (en) * 2007-03-16 2008-12-18 Multigene Vascular Systems, Inc. Compositions and methods for treating ophthalmic disorders
WO2023028004A1 (en) * 2021-08-23 2023-03-02 Avirmax, Inc. Compositions and methods for transgene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281469T1 (de) * 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
CA2375617A1 (en) * 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Targeted angiogenesis

Also Published As

Publication number Publication date
US20060094657A1 (en) 2006-05-04
ATE348629T1 (de) 2007-01-15
AU2490200A (en) 2000-08-01
WO2000041712A1 (en) 2000-07-20
EP1146891B1 (de) 2006-12-20
CA2359461A1 (en) 2000-07-20
JP2002534475A (ja) 2002-10-15
AU2004203652A1 (en) 2004-09-02
US20030191055A1 (en) 2003-10-09
HK1041447A1 (zh) 2002-07-12
EP1146891A4 (de) 2002-07-17
EP1146891A1 (de) 2001-10-24
AU773050B2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
HRP20080467A2 (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60032459D1 (de) Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
MX9604434A (es) Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales.
TR199901104T2 (xx) Farmas�tik bile�ikler.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
DE69815788D1 (de) Verwendung von Des-Aspartate Angiotensin I zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung von Atherosclerose, Neointimabildung und Restenose
PT1206256E (pt) Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
HK1047695A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
ZA200309642B (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia.
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE60025705D1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
DE50012015D1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
EP1194162A4 (de) Zusammensetzungen und methoden zur vorbeugung, behandlung und nachweis von tuberhulose und andren krankheiten

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee